Navigation Links
Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe
Date:7/29/2010

EMERYVILLE, Calif., July 29 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba.

"We are pleased with the outcome of our Scientific Advice meetings with the European Medicines Agency. We are eager to put this guidance to use and to start our late stage pivotal studies for Menerba," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer.

"There are 37 million menopausal women in Europe and, with a European marketing authorization, we expect the European market demand to be strong for a safe and efficacious alternative to hormone therapy for the treatment of hot flashes," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer.

The Company has also had a meeting with the U.S. Food and Drug Administration (FDA) on the development of Menerba in the U.S., and looks forward to providing more details when the minutes of the meeting are released.

About Menerba

Menerba is an oral, botanically-derived drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-beta) selective drug, developed as a safer alternative to the products currently on the market, which have been shown to increase the risk for breast and uterine cancers. Clinical tests conducted thus far, following the specific guidance of the FDA, have indicated that Menerba is effective and safe.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2010 Financial Results on Wednesday, August 4, 2010
2. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
3. Bionovo Announces 2009 Highlights and Year-End Financial Results
4. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
5. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
6. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
7. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
8. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
9. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
10. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
11. Bionovo Announces First Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 Shire ... Jeff Poulton , Chief Financial Officer, will present at ... Boston, MA on Wednesday, May 04, 2016, ... webcast will be available on the Presentations and Webcasts section ... replay of the webcast will be available on this same ...
(Date:4/27/2016)... , April 27, 2016 ... to reach USD 2.06 billion by 2022, according ... Inc. Increasing consumer awareness towards a healthy lifestyle ... next seven years.      (Logo: ... intake coupled with rising health treatment expenditure has ...
(Date:4/26/2016)... , April 26, 2016 US ... forecast to expand 4.9 percent annually to $27.6 ... other healthcare facilities to decrease rates of healthcare-associated ... prevention supplies, equipment, and services.  Although declining, the ... significantly above targeted levels set by the CDC.  ...
Breaking Medicine Technology:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... the Year at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® ... innovation, and safety. The Healthy Ageing division can include everything from antioxidants, lipids, ...
(Date:4/28/2016)... ... 28, 2016 , ... USA Medical Card reminds us that May is National Stroke Awareness Month. ... fourth leading cause of death in the United States; someone has one every 40 seconds. ... in individuals under 65 years old. A stroke is when blood flow to the ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... in the development of miniature microphones and headsets announced today that the US ... method of integrating in-earphones into a structure. This innovative design creates a lightweight ...
(Date:4/28/2016)... Cary, NC (PRWEB) , ... April 28, 2016 ... ... to announce it has partnered with Community Oncology Pharmacy Association (COPA) to develop ... elevate the practice of oncology by introducing an accreditation distinction. ACHC provides a ...
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households across the ... USA Medical Prescription Assistance Program. They are customized to reflect the specific health ... include a ready-to-use, state-themed card and, in the near future, material that highlights ...
Breaking Medicine News(10 mins):